1. Bokeriya LA, Zatevakhin II, Kirienko AI, Andriyashkin AV, Andriyashkin V., Arutyunov GP, Barinov VE, Bitsadze VO, Bodykhov MK, Britov AN, Butenko AV, Vavilova TV, Vorobyova NA, Voskanyan UE, Gavrilenko AV, Galstyan GM, Gelfand BR, Gilyarov MU, Golubev GSh, Zamyatin MN, Zolotukhin IA, Kobalava ZhD, Katelnickij II, Kopyonkin SS, Kuznetsov MR, Leont’ev SG, Lobastov KV, Lubnin AU, Makatsariya AD, Moiseev VS, Momot AP, Ostryakova EV, Panchenko EP, Perekhodov SN, Piradov MA, Poddubnaya IV, Pokrovskii AV, Protsenko DN, Prudkov MI, Pryadko SI, Pyregov AV, Reshetnyak TM, Ryabinkina UV, Sapelkin SV, Semenova MN, Smirnov SV, Sokolov VA, Stakhovskaya LV, Stoiko UM, Sulimov VA, Sukhikh GT, Tereshchenko SN, Fokin AA, Khruslov MV, Shevela AI, Shimanko AI, Shulutko AM, Yavelov IS, Yakhontov DI. Russian guidelines for the diagnosis, danger and prevention of venous thromboembolic complications. Flebologiya. 2015;9(4):3-52. (In Russ.)
2. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism
3. Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism
4. Vanderschueren S, Dens J, Kerdsinchai P, Desmet W, Vrolix M, De Man F, Van den Heuvel P, Hermans L, Collen D, Van de Werf F. Randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarction. Am Heart J. 1997;134:213-219
5. Markin SS, Semenov AM, Markov VA, Nizov AA, Ponomarev EA, Lebedev PA. Clinical trial of fibrinselective thrombolytic pharmaceutical agent Fortelyzin (III Phase). Rudn Journal of Medicine. 2012;1:105-110. (In Russ.)